The strategy, combining a PI3Kα inhibitor with a CDK4/6i and ET, was tested in 1L HR+/HER2− advanced BC on patients with primary endocrine resistance (disease progression during or <12 months from adjuvant ET) [68]. This evidence concerns the gene ERBB2 and breast cancer.